Gabriel Hortobagyi, MD, MACP, FASCO

Articles by Gabriel Hortobagyi, MD, MACP, FASCO

Advances Treating HR+ Metastatic Breast Cancer

ByGabriel Hortobagyi, MD, MACP, FASCO,Sara A. Hurvitz, MD,Aditya Bardia, MD

December 6th 2021

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.

Novel Therapies Under Investigation for HR+ MBC

ByGabriel Hortobagyi, MD, MACP, FASCO,Aditya Bardia, MD,Sara A. Hurvitz, MD

December 6th 2021

An overview of key presentations from ESMO 2021 that continues studying the potential effect of novel-based treatment options for use in hormone receptor-positive metastatic breast cancer.

Treatment Advances in HR+/HER2- MBC

ByJoyce O'Shaughnessy, MD,Neil M. Iyengar, MD,Sarah L. Sammons, MD,Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

Novel Agents Under Study for HR+/HER2- MBC

ByJoyce O'Shaughnessy, MD,Sarah L. Sammons, MD,Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

A panel of breast oncologists highlight exciting treatment strategies being explored in clinical trials to help address treatment limitations in HR+/HER2- metastatic breast cancer.

PI3K Inhibitors for HR+ MBC

ByGabriel Hortobagyi, MD, MACP, FASCO,Sara A. Hurvitz, MD

November 29th 2021

The relevance of PIK3CA mutations in terms of the pathophysiology of HR-positive metastatic breast cancer, and lessons learned in practice and via clinical studies in terms of sequencing therapy with PI3K inhibitors.

Sequencing Therapy in HR+/HER2- MBC

ByJoyce O'Shaughnessy, MD,Neil M. Iyengar, MD,Sarah L. Sammons, MD,Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

Managing Patients With HR+ MBC on PI3K Therapy

ByJoyce O'Shaughnessy, MD,Gabriel Hortobagyi, MD, MACP, FASCO,Sarah L. Sammons, MD,Neil M. Iyengar, MD

November 22nd 2021

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

PI3K Inhibitors for PIK3CA-Mutated HR+ MBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Neil M. Iyengar, MD,Gabriel Hortobagyi, MD, MACP, FASCO

November 15th 2021

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

CDK4/6 Treatment Selection for HR+/HER2- MBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Gabriel Hortobagyi, MD, MACP, FASCO,Sarah Sammons, MD, Duke Cancer Institute,Neil M. Iyengar, MD

November 8th 2021

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Neil M. Iyengar, MD,Sarah Sammons, MD, Duke Cancer Institute,Gabriel Hortobagyi, MD, MACP, FASCO

November 1st 2021

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

MONALEESA Data in HR+/HER2- MBC: Sequencing Therapy

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Neil M. Iyengar, MD,Gabriel Hortobagyi, MD, MACP, FASCO

October 25th 2021

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.

Ribociclib + ET for HR+/HER2- MBC: QoL and OS Data

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Neil M. Iyengar, MD,Gabriel Hortobagyi, MD, MACP, FASCO

October 25th 2021

Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.

HR+/HER2- MBC: Updated OS Data From MONALEESA-2

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Gabriel Hortobagyi, MD, MACP, FASCO,Sarah Sammons, MD, Duke Cancer Institute

October 18th 2021

Reactions to new overall survival results from the MONALEESA-2 study in patients with HR+/HER2- advanced breast cancer in the first-line setting.

HR+ MBC: Prognostic Factors and Treatment Planning

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Gabriel Hortobagyi, MD, MACP, FASCO,Neil M. Iyengar, MD,Sarah Sammons, MD, Duke Cancer Institute

October 11th 2021

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Identifying PIK3CA Mutations in HR+ HER2- MBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Gabriel Hortobagyi, MD, MACP, FASCO,Neil M. Iyengar, MD,Sarah Sammons, MD, Duke Cancer Institute

October 11th 2021

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.